plicamycin has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bond, GL; Hamir, A; Iwakuma, T; Jackson, JG; Johnson, DG; Levine, AJ; Lozano, G; Maccio, DR; Pant, V; Post, SM; Quintás-Cardama, A | 1 |
| Blumenthal, SG; Dittmer, J; Lindemann, RK; Manns, J; Thomssen, C; Vetter, M; Wesselborg, S | 1 |
2 other study(ies) available for plicamycin and Neoplasms
| Article | Year |
|---|---|
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Genes, p53; Genetic Predisposition to Disease; Humans; Mice; Neoplasms; Nuclear Proteins; Plicamycin; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Signal Transduction; Sp1 Transcription Factor; Tumor Suppressor Protein p53 | 2010 |
Ets1 is an effector of protein kinase Calpha in cancer cells.
Topics: Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Cell Shape; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Plicamycin; Protein Kinase C; Protein Kinase C-alpha; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; RNA Interference; Transcription Factors; Ultraviolet Rays | 2005 |